News
Pharmaceutical Technology on MSN18h
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapyThe company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback